Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on September 15, 2005
Schizophrenia Bulletin 2005 31(4):793-794; doi:10.1093/schbul/sbi065
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
31/4/793    most recent
sbi065v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Carpenter, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carpenter, W., Jr
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Unmet Therapeutic Needs

The first 10% of the full text of this article appears below.

Modern pharmacotherapy for schizophrenia began with the introduction of chlorpromazine in 1952. About the same time principles from social psychiatry were being implemented, and the locus of care shifted away from chronic care hospitals. Empirically validated forms of psychosocial treatment have now joined drug treatment in evidence-based practice. But it has been difficult to robustly alter long-term outcome.1 Current treatments appear most robust in effecting psychosis,2 and there has been . . . [Full Text of this Article]

William Carpenter, Jr

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?